Biological markers of oxidative stress: Applications to cardiovascular research and practice☆

Oxidative stress is a common mediator in pathogenicity of established cardiovascular risk factors. Furthermore, it likely mediates effects of emerging, less well-defined variables that contribute to residual risk not explained by traditional factors. Functional oxidative modifications of cellular proteins, both reversible and irreversible, are a causal step in cellular dysfunction. Identifying markers of oxidative stress has been the focus of many researchers as they have the potential to act as an “integrator” of a multitude of processes that drive cardiovascular pathobiology. One of the major challenges is the accurate quantification of reactive oxygen species with very short half-life. Redox-sensitive proteins with important cellular functions are confined to signalling microdomains in cardiovascular cells and are not readily available for quantification. A popular approach is the measurement of stable by-products modified under conditions of oxidative stress that have entered the circulation. However, these may not accurately reflect redox stress at the cell/tissue level. Many of these modifications are “functionally silent”. Functional significance of the oxidative modifications enhances their validity as a proposed biological marker of cardiovascular disease, and is the strength of the redox cysteine modifications such as glutathionylation. We review selected biomarkers of oxidative stress that show promise in cardiovascular medicine, as well as new methodologies for high-throughput measurement in research and clinical settings. Although associated with disease severity, further studies are required to examine the utility of the most promising oxidative biomarkers to predict prognosis or response to treatment.

[1]  D. Giustarini,et al.  Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress. , 2006, Clinical chemistry.

[2]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[3]  Marie-Luise Brennan,et al.  Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. , 2003, Circulation.

[4]  Thomas J. Wang,et al.  Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction , 2011, Circulation.

[5]  E. Rimm,et al.  Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  Balaraman Kalyanaraman,et al.  Peroxynitrite modification of low‐density lipoprotein leads to recognition by the macrophage scavenger receptor , 1993, FEBS letters.

[7]  K. Channon,et al.  Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations , 2012, Current medicinal chemistry.

[8]  P. Holvoet,et al.  Oxidized LDL and HDL: antagonists in atherothrombosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  J. Thompson,et al.  Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. , 1998, Biochemistry.

[10]  M. Watkins,et al.  S-glutathionylation uncouples eNOS and regulates its cellular and vascular function , 2011 .

[11]  G. FitzGerald,et al.  Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS , 2003, Circulation.

[12]  R. Radi,et al.  Biochemistry of protein tyrosine nitration in cardiovascular pathology. , 2007, Cardiovascular research.

[13]  G. Figtree,et al.  &bgr;3 Adrenergic Stimulation of the Cardiac Na+-K+ Pump by Reversal of an Inhibitory Oxidative Modification , 2010, Circulation.

[14]  S. Tsimikas Oxidized low-density lipoprotein biomarkers in atherosclerosis , 2006, Current atherosclerosis reports.

[15]  G. Figtree,et al.  Reversible Oxidative Modification: A Key Mechanism of Na+-K+ Pump Regulation , 2009, Circulation research.

[16]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[17]  G. Figtree,et al.  Oxidative regulation of the Na(+)-K(+) pump in the cardiovascular system. , 2012, Free radical biology & medicine.

[18]  M. Reilly,et al.  8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. , 1997, Circulation.

[19]  A. Scaloni,et al.  Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. , 2005, Mass spectrometry reviews.

[20]  K. Kędziora-Kornatowska,et al.  Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes. , 1998, Clinical chemistry and laboratory medicine.

[21]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[22]  G. Biessels,et al.  Glutathione and α‐lipoate in diabetic rats: nerve function, blood flow and oxidative state , 2001, European journal of clinical investigation.

[23]  B. Freeman,et al.  NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? , 2003, Trends in biochemical sciences.

[24]  S. Hamilton,et al.  Identification of Cysteines Involved in S-Nitrosylation, S-Glutathionylation, and Oxidation to Disulfides in Ryanodine Receptor Type 1* , 2006, Journal of Biological Chemistry.

[25]  D. Harrison,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[26]  S. Hazen,et al.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.

[27]  T. Niwa,et al.  Increased glutathionyl hemoglobin in diabetes mellitus and hyperlipidemia demonstrated by liquid chromatography/electrospray ionization-mass spectrometry. , 2000, Clinical chemistry.

[28]  D. Praticò,et al.  8-Epi PGF2α Generation During Coronary Reperfusion , 1997 .

[29]  S. Hazen,et al.  Nitric oxide modulates the catalytic activity of myeloperoxidase. , 2000, The Journal of biological chemistry.

[30]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[31]  K. Shimokata,et al.  Glutathionyl hemoglobin in uremic patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis. , 2001, Kidney international. Supplement.

[32]  D. Giustarini,et al.  S-Glutathiolation in life and death decisions of the cell , 2011, Free radical research.

[33]  A. Kettle,et al.  Myeloperoxidase , 2000, Current opinion in hematology.

[34]  D. Harrison,et al.  Redox Mechanisms in Blood Vessels , 2004 .

[35]  S. Azen,et al.  Alpha-Tocopherol Supplementation in Healthy Individuals Reduces Low-Density Lipoprotein Oxidation but Not Atherosclerosis: The Vitamin E Atherosclerosis Prevention Study (VEAPS) , 2002, Circulation.

[36]  E F Schisterman,et al.  TBARS and Cardiovascular Disease in a Population-Based Sample , 2001, Journal of cardiovascular risk.

[37]  C. Hamm,et al.  Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine , 2005, Heart.

[38]  J. Morrow,et al.  Prostaglandin F2-like compounds, F2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[39]  T. Matsuo,et al.  Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes , 2001, Circulation.

[40]  D. Pimentel,et al.  S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide , 2004, Nature Medicine.

[41]  C. Shannon-Weickert BIOMARKERS , 2014, Schizophrenia Research.

[42]  A. Chait,et al.  Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[43]  J. Morrow,et al.  A Causative Role for Redox Cycling of Myoglobin and Its Inhibition by Alkalinization in the Pathogenesis and Treatment of Rhabdomyolysis-induced Renal Failure* , 1998, The Journal of Biological Chemistry.

[44]  J. Bonventre,et al.  Release of Free F2-isoprostanes from Esterified Phospholipids Is Catalyzed by Intracellular and Plasma Platelet-activating Factor Acetylhydrolases* , 2006, Journal of Biological Chemistry.

[45]  E. Rimm,et al.  Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. , 2002, Clinical chemistry.

[46]  S. Bursell,et al.  The potential use of glutathionyl hemoglobin as a clinical marker of oxidative stress. , 2000, Clinical chemistry.

[47]  P. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[48]  P. Scheffer,et al.  Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? , 2009, Clinical chemistry.

[49]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[50]  C. Meisinger,et al.  Plasma Oxidized Low-Density Lipoprotein, a Strong Predictor for Acute Coronary Heart Disease Events in Apparently Healthy, Middle-Aged Men From the General Population , 2005, Circulation.

[51]  J. Morrow,et al.  Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  U. Singh,et al.  Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. , 2008, The American journal of cardiology.

[53]  C. Capeillère-Blandin,et al.  Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. , 1998, The Biochemical journal.

[54]  S. Ito,et al.  Angiotensin II Type 1 Receptor Blockers Reduce Urinary Oxidative Stress Markers in Hypertensive Diabetic Nephropathy , 2006, Hypertension.

[55]  A. Shah,et al.  Redox Signaling in Cardiac Physiology and Pathology , 2012, Circulation research.

[56]  M. Leist,et al.  Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. , 1999, The American journal of pathology.

[57]  Daniel Steinberg,et al.  Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.

[58]  C. Mueller,et al.  Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. , 2008, Clinical chemistry.

[59]  E. Kilpatrick,et al.  A comparison of methods for the measurement of 8-isoPGF2α : a marker of oxidative stress , 2011, Annals of clinical biochemistry.

[60]  D. Slatter,et al.  The importance of lipid-derived malondialdehyde in diabetes mellitus , 2000, Diabetologia.

[61]  K. Sunagawa,et al.  Effects of Valsartan or Amlodipine on Endothelial Function and Oxidative Stress after One Year Follow-up in Patients with Essential Hypertension , 2008, Clinical and experimental hypertension.

[62]  J. Heinecke,et al.  Artifact-free quantification of free 3-chlorotyrosine, 3-bromotyrosine, and 3-nitrotyrosine in human plasma by electron capture-negative chemical ionization gas chromatography mass spectrometry and liquid chromatography-electrospray ionization tandem mass spectrometry. , 2002, Analytical biochemistry.

[63]  J. Morrow Quantification of Isoprostanes as Indices of Oxidant Stress and the Risk of Atherosclerosis in Humans , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[64]  G. Kitas,et al.  Validation of a novel ELISA for measurement of MDA-LDL in human plasma. , 2003, Free radical biology & medicine.

[65]  R. Jacob,et al.  Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. , 2004, Journal of the American College of Cardiology.

[66]  G. Figtree,et al.  Reversible oxidative modification: implications for cardiovascular physiology and pathophysiology. , 2010, Trends in cardiovascular medicine.

[67]  S. Hazen,et al.  Tyrosine Nitration Impairs Mammalian Aldolase A Activity* , 2004, Molecular & Cellular Proteomics.

[68]  D. Steinberg,et al.  The oxidative modification hypothesis of atherogenesis: an overview. , 2000, Free radical biology & medicine.

[69]  R. Stocker,et al.  Correlation between intima-to-media ratio, apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in human atherosclerosis. , 2001, Free radical biology & medicine.

[70]  M. Duncan,et al.  A review of approaches to the analysis of 3-nitrotyrosine , 2003, Amino Acids.

[71]  P. Montuschi,et al.  Isoprostanes: markers and mediators of oxidative stress , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  J. Morrow,et al.  The isoprostanes: unique products of arachidonic acid oxidation-a review. , 2003, Current medicinal chemistry.

[73]  N. Porter,et al.  Mechanisms of free radical oxidation of unsaturated lipids , 1995, Lipids.

[74]  G. FitzGerald,et al.  Indices of lipid peroxidation in vivo: strengths and limitations. , 2000, Free radical biology & medicine.

[75]  J. Weisel,et al.  Pro-thrombotic State Induced by Post-translational Modification of Fibrinogen by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.

[76]  Michael Marber,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction , 2010 .

[77]  C. Stefanadis,et al.  The role of oxidative stress in atherosclerosis. , 2009, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[78]  J. Salonen,et al.  Lipoprotein oxidation and progression of carotid atherosclerosis. , 1997, Circulation.

[79]  A. Carr,et al.  Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[80]  Stanley L. Hazen,et al.  Identification of &agr;-Chloro Fatty Aldehydes and Unsaturated Lysophosphatidylcholine Molecular Species in Human Atherosclerotic Lesions , 2003 .

[81]  M. Johansson,et al.  Glutathionylation of beta-actin via a cysteinyl sulfenic acid intermediary , 2007, BMC Biochemistry.

[82]  A. Khera,et al.  The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. , 2013, Journal of the American College of Cardiology.

[83]  F. Cambien,et al.  Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. , 2003, The New England journal of medicine.

[84]  J. Menzoian,et al.  Detection of sequence-specific tyrosine nitration of manganese SOD and SERCA in cardiovascular disease and aging. , 2006, American journal of physiology. Heart and circulatory physiology.

[85]  E. Topol,et al.  Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. , 1994, Circulation.

[86]  C. Kawai,et al.  Effects of superoxide dismutase on reperfusion arrhythmias and left ventricular function in patients undergoing thrombolysis for anterior wall acute myocardial infarction. , 1991, The American journal of cardiology.

[87]  F. Werf,et al.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. , 1998, Circulation.

[88]  R. Haworth,et al.  Increased Nitration of Sarcoplasmic Reticulum Ca2+-ATPase in Human Heart Failure , 2005, Circulation.

[89]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[90]  L. Appel,et al.  Association between cigarette smoking and lipid peroxidation in a controlled feeding study. , 1997, Circulation.

[91]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[92]  F. Aktan,et al.  Short-term gemfibrozil treatment reverses lipid profile and peroxidation but does not alter blood glucose and tissue antioxidant enzymes in chronically diabetic rats , 2004, Molecular and Cellular Biochemistry.

[93]  M. Luciak,et al.  Effect of Aminoguanidine on Erythrocyte Lipid Peroxiclation and Activities of Antioxidant Enzymes in Experimental Diabetes , 1998 .

[94]  E J Topol,et al.  Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.

[95]  Paul M. Ridker,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein , 2009 .

[96]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[97]  C. Heeschen,et al.  Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes , 2003, Circulation.

[98]  S. Przedborski,et al.  Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[99]  C. Schöneich,et al.  3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. , 2005, Biochemistry.

[100]  G. Figtree,et al.  Protein kinase‐dependent oxidative regulation of the cardiac Na+–K+ pump: evidence from in vivo and in vitro modulation of cell signalling , 2013, The Journal of physiology.

[101]  I. Rahman,et al.  Nrf2-ARE stress response mechanism: A control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases , 2010, Free radical research.

[102]  R. Radi,et al.  Protein tyrosine nitration in hydrophilic and hydrophobic environments , 2006, Amino Acids.

[103]  J. Morrow,et al.  Recent advances in the biochemistry and clinical relevance of the isoprostane pathway , 2005, Lipids.

[104]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[105]  A. Daugherty,et al.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.

[106]  K. Uchida Role of reactive aldehyde in cardiovascular diseases. , 2000, Free radical biology & medicine.